Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Daridorexant in Severe Obstructive Sleep Apnea
NCT05458193Phase 1Completed
- Sponsor
- Idorsia
- Start
- Aug 2022
- Primary completion
- Feb 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in obstructive sleep apnea (OSA) comparing Daridorexant with Placebo (2 arms). Primary endpoint: Apnea/Hypopnea Index. Started Aug 2022; status: completed.
02
Drugs
daridorexant
03
Conditions
obstructive sleep apnea (OSA)
Beyond the preview
Go deeper on NCT05458193.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05458193.